194 related articles for article (PubMed ID: 9882925)
1. Early treatment with recombinant factor VIIa results in greater efficacy with less product.
Lusher JM
Eur J Haematol Suppl; 1998; 63():7-10. PubMed ID: 9882925
[TBL] [Abstract][Full Text] [Related]
2. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
3. Approaches towards successful home treatment in patients with inhibitors.
Ingerslev J; Thykjaer H; Scheibel E
Eur J Haematol Suppl; 1998; 63():11-4. PubMed ID: 9882926
[TBL] [Abstract][Full Text] [Related]
4. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
5. Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment.
Lusher JM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S111-4. PubMed ID: 9819040
[TBL] [Abstract][Full Text] [Related]
6. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?
Brackmann HH; Effenberger W; Hess L; Schwaab R; Oldenburg J
Eur J Haematol Suppl; 1998; 63():18-23. PubMed ID: 9882928
[TBL] [Abstract][Full Text] [Related]
7. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
8. Recombinant factor VIIa in joint and muscle bleeding episodes.
Bech RM
Haemostasis; 1996; 26 Suppl 1():135-8. PubMed ID: 8904188
[TBL] [Abstract][Full Text] [Related]
9. Pharmaco-economic aspects of inhibitor treatment.
Goudemand J
Eur J Haematol Suppl; 1998; 63():24-7. PubMed ID: 9882929
[TBL] [Abstract][Full Text] [Related]
10. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
Stewart AJ; Hanley JP; Ludlam CA
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
[TBL] [Abstract][Full Text] [Related]
11. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors.
Lusher JM
Haemostasis; 1996; 26 Suppl 1():124-30. PubMed ID: 8904186
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group.
Lusher JM; Roberts HR; Davignon G; Joist JH; Smith H; Shapiro A; Laurian Y; Kasper CK; Mannucci PM
Haemophilia; 1998 Nov; 4(6):790-8. PubMed ID: 10028299
[TBL] [Abstract][Full Text] [Related]
14. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
15. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Chuansumrit A; Isarangkura P; Angchaisuksiri P; Sriudomporn N; Tanpowpong K; Hathirat P; Jorgensen LN
Haemophilia; 2000 Mar; 6(2):61-5. PubMed ID: 10781189
[TBL] [Abstract][Full Text] [Related]
16. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
Nakar C; Cooper DL; DiMichele D
Haemophilia; 2010 Jul; 16(4):625-31. PubMed ID: 20158526
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
Petrini P; Klementz G
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
[TBL] [Abstract][Full Text] [Related]
18. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
Liebman HA; Chediak J; Fink KI; Galvez AG; Shah PC; Sham RL
Am J Hematol; 2000 Mar; 63(3):109-13. PubMed ID: 10679799
[TBL] [Abstract][Full Text] [Related]
19. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
Arkin S; Blei F; Fetten J; Foulke R; Gilchrist GS; Heisel MA; Key N; Kisker CT; Kitchen C; Shafer FE; Shah PC; Strickland D
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):255-9. PubMed ID: 10870806
[TBL] [Abstract][Full Text] [Related]
20. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII.
Lusher JM
Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S45-9. PubMed ID: 10850564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
